Genome-wide somatic copy number alterations (SCNAs) identified in ctDNA from plasma samples of patients with advanced EGFR-mutated lung adenocarcinoma represent another mechanism of resistance, particularly to third-generation TKIs such as osimertinib, which are associated with reduced therapeutic response rates [78]. This evidence concerns the gene EGFR and lung adenocarcinoma.